Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront HSCT in Myelodysplastic Syndrome
NCT06235398Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2024
- Primary completion
- Feb 2028
01
Overview
Phase 2, open-label, single-arm trial in myelodysplastic syndromes (MDS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Disease-free survival at 2 years. Planned start Feb 2024; status: not yet recruiting.
02
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT06235398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235398.